IOZK - Immunologisch Onkologisches Zentrum Köln
DE | ENG | RU

Role of CTGF in Sensitivity to Hyperthermia in Ovarian and Uterine Cancers.
Nov. 2016 | Hatakeyama, Hiroto; Wu, Sherry Y; Lyons, Yasmin A; Pradeep, Sunila; Wang, Wanqin; Huang, Qian; Court, Karem A; Liu, Tao; Nie, Song; Rodriguez-Aguayo, Cristian; Shen, Fangrong; Huang, Yan; Hisamatsu, Takeshi; Mitamura, Takashi; Jennings, Nicholas; Shim, Jeajun; Dorniak, Piotr L; Mangala, Lingegowda S; Petrillo, Marco; Petyuk, Vladislav A; Schepmoes, Athena A; Shukla, Anil K; Torres-Lugo, Madeline; Lee, Ju-Seog; Rodland, Karin D; Fagotti, Anna; Lopez-Berestein, Gabriel; Li, Chun; Sood, Anil K
Even though hyperthermia is a promising treatment for cancer, the relationship between specific temperatures and clinical benefits and predictors of sensitivity of cancer to hyperthermia is poorly understood. Ovarian and uterine tumors have diverse hyperthermia sensitivities. Integrative analyses of the specific gene signatures and the differences in response to hyperthermia between hyperthermia-sensitive and -resistant cancer cells identified CTGF as a key regulator of sensitivity. CTGF silencing sensitized resistant cells to hyperthermia. CTGF small interfering RNA (siRNA) treatment also sensitized resistant cancers to localized hyperthermia induced by copper sulfide nanoparticles and near-infrared laser in orthotopic ovarian cancer models. CTGF silencing aggravated energy stress induced by hyperthermia and enhanced apoptosis of hyperthermia-resistant cancers. PMID 27806300

Dendritic cell immunotherapy in uterine cancer.
Nov. 2014 | Coosemans, An; Tuyaerts, Sandra; Vanderstraeten, Anke; Vergote, Ignace; Amant, Frédéric; Van Gool, Stefaan W
Uterine cancer is the most common pelvic gynecological malignancy. Uterine sarcomas and relapsed uterine carcinomas have limited treatment options. The search for new therapies is urgent. Dendritic cell (DC) immunotherapy holds much promise, though has been poorly explored in uterine cancer. This commentary gives an insight in existing DC immunotherapy studies in uterine cancer and summarizes the possibilities and the importance of the loading of tumor antigens onto DC and their subsequent maturation. However, the sole application of DC immunotherapy to target uterine cancer will be insufficient because of tumor-induced immunosuppression, which will hamper the establishment of an effective anti-tumor immune response. The authors give an overview on the limited existing immunosuppressive data and propose a novel approach on DC immunotherapy in uterine cancer. PMID 25424788

Wilms' tumor gene 1 immunotherapy in pelvic gynecological malignancies.
Mai 2014 | Coosemans, A; Vergote, I; Van Gool, S W
Pelvic gynecological malignancies account for 6% of all cancers. In the relapsed state, classical treatments are limited. There is an urgent need for new and personalized treatment. Wilms' tumor gene 1 (WT1) is the most important tumor-associated antigen. Although highly present in gynecological tumors, active immunotherapy against it is still underexplored. This review gives an insight into the importance of WT1 in pelvic gynecological malignancies and the first taken steps into the world of WT1 immunotherapy. PMID 24784346

Wilms' Tumor Gene 1 (WT1)--loaded dendritic cell immunotherapy in patients with uterine tumors: a phase I/II clinical trial.
Dez. 2013 | Coosemans, An; Vanderstraeten, Anke; Tuyaerts, Sandra; Verschuere, Tina; Moerman, Philippe; Berneman, Zwi N; Vergote, Ignace; Amant, Frédéric; VAN Gool, Stefaan W
Treatment options are limited in uterine cancer, leading to a poor prognosis. Overexpression of Wilms' tumor gene 1 (WT1), the highest ranked tumor antigen, is attractive for immunotherapy. PMID 24324087

Search